Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Injection 2 mg and does not impact EYLEA HD® (aflibercept) Injection 8 mg. We continue to believe that Amgen is infringing our patent rights, and today’s decision denying our request for a ...

Approval of Amgen’s Aflibercept Biosimilar: On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to ...

The lawsuit was related to a biosimilar of its lead drug Eylea (aflibercept 2 mg ... REGN filed a patent infringement lawsuit against Amgen in the U.S. District Court for the Central District ...

The FDA recently approved Amgen’s biosimilar of Eylea — Pavblu. This is the fifth biosimilar approved for Eylea. The FDA had earlier approved Biocon Biologics's Yesafili (aflibercept-jbvf) and Samsung ...

The FDA recently approved Amgen’s biosimilar of Eylea — Pavblu. This is the fifth biosimilar approved for Eylea. The FDA had ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

REGN)'s motion for a preliminary injunction against Amgen (NASDAQ:AMGN), clearing the way for the launch of a biosimilar version of aflibercept (Eylea). RBC Capital commented, "The expectations ...